Your browser doesn't support javascript.
Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks et al.
Sparks, Jeffrey A; Wallace, Zachary S; Seet, Andrea M; Robinson, Philip C; Machado, Pedro M; Yazdany, Jinoos.
  • Sparks JA; Department of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA jsparks@bwh.harvard.edu zswallace@mgh.harvard.edu.
  • Wallace ZS; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Seet AM; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA jsparks@bwh.harvard.edu zswallace@mgh.harvard.edu.
  • Robinson PC; Rheumatology Unit, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Machado PM; Medicine/Rheumatology, University of California San Francisco, San Francisco, California, USA.
  • Yazdany J; Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia.
Ann Rheum Dis ; 2021 Aug 13.
Article in English | MEDLINE | ID: covidwho-1356919
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Year: 2021 Document Type: Article